Another kinase inhibitor, Sorafenib (SOR), acts by inhibiting several different kinases (RAF-1, VEGF, c-KIT, PDGFR, ERK, and FLT3) involved in tumor cell proliferation and angiogenesis. The gene discussed is PDGFRB; the disease is neoplasm.